Medical Xpress: Researchers identify new target to treat pediatric brain tumors
UC's Timothy Phoenix part of team researching pediatric diffuse midline gliomas
Researchers have identified the role of a key gene that helps a type of pediatric brain tumor to grow, which could help develop better treatments.
Diffuse midline gliomas, formerly referred to as Diffuse Intrinsic Pontine Gliomas (DIPG), are tumors of the primary central nervous system, meaning they begin in the brain or spinal cord. Each year, approximately 200-300 children in the United States are diagnosed with this tumor that is commonly located in the brain stem, with a nearly zero percent survival rate.
Recent research published by the University of Cincinnati's Timothy Phoenix, PhD, assistant professor in UC’s James L. Winkle College of Pharmacy Division of Pharmaceutical Sciences and a UC Cancer Center member, as well as colleagues from the Dana-Farber Cancer Insitute, Broad Institute of MIT and Harvard and others, focused on a gene called PPM1D.
The researchers found PPM1D is a gene that helps promote the growth of the tumors and that drugs could potentially target this gene to treat patients. In animal models of the tumors, the tumor cells died when the gene was disabled.
Read the Medical Xpress article.
Read more about Dr. Phoenix's research into diffuse midline gliomas.
Featured photo at top of Dr. Phoenix: Photo/Colleen Kelley/UC Creative + Brand
Related Stories
UC expert offers advice to Cincinnati on climate change
August 14, 2026
In an op-ed, UC Associate Professor Bob Hyland talks about ways Cincinnati can become more resilient in face of climate change.
UC named a best employer in Ohio by Forbes
August 14, 2026
Forbes ranks the University of Cincinnati No. 24 on its 2026 America’s Best Employers By State list for Ohio, recognizing UC’s strong workplace culture and employee experience.
Mistakes to avoid when shopping for a product dupe
August 13, 2026
The University of Cincinnati’s Kelly Dobos was featured in an AARP article discussing ways to determine if “dupe” cosmetic products really are comparable to the more expensive name brand.